Viking Therapeutics

Viking Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapies for metabolic and endocrine disorders. Its lead candidate is VK2735, a dual GLP-1/GIP receptor agonist in development for obesity, with both subcutaneous and oral formulations. The company also has other programs, including VK2809, a liver-selective thyroid hormone receptor beta agonist for metabolic liver disease.